Asset Details
Do you wish to reserve the book?
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Do you wish to request the book?
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
2012
Overview
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer. Adding an mTOR inhibitor to an aromatase inhibitor improved outcomes in patients who had disease progression during hormone therapy.
Endocrine therapy is the cornerstone of treatment for patients with hormone-receptor (HR)–positive advanced breast cancer. In postmenopausal patients, aromatase inhibitors (e.g., letrozole and anastrozole) have become the treatment of choice in first-line therapy.
1
–
5
Unfortunately, not all patients have a response to first-line endocrine therapy (primary or de novo resistance), and even patients who have a response will eventually relapse (acquired resistance). On disease progression, second-line treatment options include other classes of aromatase inhibitors (steroidal or nonsteroidal) and the estrogen-receptor (ER) antagonists fulvestrant and tamoxifen.
6
,
7
The study of resistance to endocrine therapies in HR-positive breast cancer has aimed at . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Androstadienes - adverse effects
/ Androstadienes - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Aromatase Inhibitors - adverse effects
/ Aromatase Inhibitors - therapeutic use
/ Biological and medical sciences
/ Breast Neoplasms - chemistry
/ Breast Neoplasms - drug therapy
/ Dyspnea
/ Fatigue
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Pharmacology. Drug treatments
/ Receptor, Epidermal Growth Factor - analysis
/ Sirolimus - analogs & derivatives
/ Stomatitis - chemically induced
/ Survival
/ TOR Serine-Threonine Kinases - antagonists & inhibitors
/ Tumors
